Recent progress in mRNA cancer vaccines

References

• Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355–12. doi:10.1126/science.aar7112.
   PubMed Web of Science ®Google Scholar
• Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R. mRNA Cancer vaccines. Recent Results Cancer Res, 2016;209:61–85. doi:10.1007/978-3-319-42934-2_5.
   PubMedGoogle Scholar
• Weissman D, Karikó K. mRNA: fulfilling the promise of gene therapy. Mol Ther. 2015;23(9):1416–17. doi:10.1038/mt.2015.138.
   PubMed Web of Science ®Google Scholar
• Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022;3(8):911–26. doi:10.1038/s43018-022-00418-6.
   PubMedGoogle Scholar
• Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020;65:14–20. doi:10.1016/j.coi.2020.01.008.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–71. doi:10.1038/s41586-020-2622-0.
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41. doi:10.1186/s12943-021-01335-5.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2022;55(1):2–12. doi:10.1021/acs.accounts.1c00544.
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–8. doi:10.1126/science.1690918.
   PubMed Web of Science ®Google Scholar
• Martinon F, Krishnan S, Lenzen G, Magné R, Gomard E, Guillet JG, Lévy JP, Meulien P. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol. 1993;23(7):1719–22. doi:10.1002/eji.1830230749.
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184(2):465–72. doi:10.1084/jem.184.2.465.
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature. 2001;413(6857):732–8. doi:10.1038/35099560.
   PubMed Web of Science ®Google Scholar
• Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303(5663):1529–31. doi:10.1126/science.1093616.
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303(5663):1526–29. doi:10.1126/science.1093620.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740–45. doi:10.1038/35047123.
   PubMed Web of Science ®Google Scholar
• Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–75. doi:10.1016/j.immuni.2005.06.008.
   PubMed Web of Science ®Google Scholar
• Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–40. doi:10.1038/mt.2008.200.
   PubMed Web of Science ®Google Scholar
• Cullis PR, Chonn A. Recent advances in liposome technologies and their applications for systemic gene delivery. Adv Drug Deliv Rev. 1998;30(1–3):73–83. doi:10.1016/s0169-409x(97)00108-7.
   PubMed Web of Science ®Google Scholar
• Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345–51. doi:10.1016/j.jconrel.2015.08.007.
   PubMed Web of Science ®Google Scholar
• Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215–29. doi:10.1038/s41571-020-00460-2.
   PubMed Web of Science ®Google Scholar
• Bae H, Coller J. Codon optimality-mediated mRNA degradation: linking translational elongation to mRNA stability. Mol Cell. 2022;82(8):1467–76. doi:10.1016/j.molcel.2022.03.032.
   PubMed Web of Science ®Google Scholar
• Hanson G, Coller J. Codon optimality, bias and usage in translation and mRNA decay. Nat Rev Mol Cell Biol. 2018;19(1):20–30. doi:10.1038/nrm.2017.91.
   PubMed Web of Science ®Google Scholar
• Shanmugasundaram M, Senthilvelan A, Kore AR. Recent advances in modified Cap Analogs: synthesis, biochemical properties, and mRNA based vaccines. Chem Rec. 2022;22(8):e202200005. doi:10.1002/tcr.202200005.
   PubMed Web of Science ®Google Scholar
• Ramanathan A, Robb GB, Chan SH. mRNA capping: biological functions and applications. Nucleic Acids Res. 2016;44(16):7511–26. doi:10.1093/nar/gkw551.
   PubMed Web of Science ®Google Scholar
• Ohno H, Akamine S, Mochizuki M, Hayashi K, Akichika S, Suzuki T, Saito H. Versatile strategy using vaccinia virus-capping enzyme to synthesize functional 5’ cap-modified mRNAs. Nucleic Acids Res. 2023;51(6):e34. doi:10.1093/nar/gkad019.
   PubMed Web of Science ®Google Scholar
• Nwokeoji AO, Chou T, Nwokeoji EA. Low resource integrated platform for production and analysis of capped mRNA. ACS Synth Biol. 2023;12(1):329–39. doi:10.1021/acssynbio.2c00609.
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo D. Molecular mechanisms of coronavirus RNA capping and methylation. Virol Sin. 2016;31(1):3–11. doi:10.1007/s12250-016-3726-4.
   PubMed Web of Science ®Google Scholar
• Henderson JM, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N, McReynolds T, Cabral CR, Escamilla-Powers JR, Houston ME. Cap 1 messenger RNA synthesis with Co-transcriptional CleanCap(®) analog by in vitro transcription. Curr Protoc. 2021;1(2):e39. doi:10.1002/cpz1.39.
   PubMedGoogle Scholar
• Mockey M, Gonçalves C, Dupuy FP, Lemoine FM, Pichon C, Midoux P. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun. 2006;340(4):1062–8. doi:10.1016/j.bbrc.2005.12.105.
   PubMed Web of Science ®Google Scholar
• Despic V, Jaffrey SR. mRNA ageing shapes the Cap2 methylome in mammalian mRNA. Nature. 2023;614(7947):358–66. doi:10.1038/s41586-022-05668-z.
   PubMed Web of Science ®Google Scholar
• Schuster SL, Hsieh AC. The untranslated regions of mRnas in cancer. Trends Cancer. 2019;5(4):245–62. doi:10.1016/j.trecan.2019.02.011.
   PubMed Web of Science ®Google Scholar
• Kozak M. Leader length and secondary structure modulate mRNA function under conditions of stress. Mol Cell Biol. 1988;8(7):2737–44. doi:10.1128/MCB.8.7.2737.
   PubMed Web of Science ®Google Scholar
• Kozak M. Circumstances and mechanisms of inhibition of translation by secondary structure in eucaryotic mRNAs. Mol Cell Biol. 1989;9(11):5134–142. doi:10.1128/MCB.9.11.5134.
   PubMed Web of Science ®Google Scholar
• Trepotec Z, Aneja MK, Geiger J, Hasenpusch G, Plank C, Rudolph C. Maximizing the translational yield of mRNA therapeutics by minimizing 5’-UTRs. Tissue Eng Part A. 2019;25(1–2):69–79. doi:10.1089/ten.TEA.2017.0485.
   PubMed Web of Science ®Google Scholar
• Andreassi C, Riccio A. To localize or not to localize: mRNA fate is in 3‘UTR ends. Trends Cell Biol. 2009;19(9):465–74. doi:10.1016/j.tcb.2009.06.001.
   PubMed Web of Science ®Google Scholar
• Jia L, Qian SB. Therapeutic mRNA engineering from head to Tail. Acc Chem Res. 2021;54(23):4272–82. doi:10.1021/acs.accounts.1c00541.
   PubMed Web of Science ®Google Scholar
• Mayr C. Regulation by 3′-untranslated regions. Annu Rev Genet. 2017;51(1):171–94. doi:10.1146/annurev-genet-120116-024704.
   PubMedGoogle Scholar
• Mayr C. What are 3′ UTRs doing? Cold Spring Harb Perspect Biol. 2019;11(10):a034728. doi:10.1101/cshperspect.a034728.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Y, Dong Y. Lipid nanoparticle-mRNA formulations for therapeutic applications. Acc Chem Res. 2021;54(23):4283–93. doi:10.1021/acs.accounts.1c00550.
   PubMed Web of Science ®Google Scholar
• Castillo-Hair SM, Seelig G. Machine learning for designing next-generation mRNA therapeutics. Acc Chem Res. 2022;55(1):24–34. doi:10.1021/acs.accounts.1c00621.
   PubMed Web of Science ®Google Scholar
• Sample PJ, Wang B, Reid DW, Presnyak V, McFadyen IJ, Morris DR, Seelig G. Human 5’ UTR design and variant effect prediction from a massively parallel translation assay. Nat Biotechnol. 2019;37(7):803–9. doi:10.1038/s41587-019-0164-5.
   PubMed Web of Science ®Google Scholar
• Presnyak V, Alhusaini N, Chen YH, Martin S, Morris N, Kline N, Olson S, Weinberg D, Baker KE, Graveley BR, et al. Codon optimality is a major determinant of mRNA stability. Cell. 2015;160(6):1111–24. doi:10.1016/j.cell.2015.02.029.
   PubMed Web of Science ®Google Scholar
• Kudla G, Lipinski L, Caffin F, Helwak A, Zylicz M, Hurst LD. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 2006;4(6):e180. doi:10.1371/journal.pbio.0040180.
   PubMed Web of Science ®Google Scholar
• Mauger DM, Cabral BJ, Presnyak V, Su SV, Reid DW, Goodman B, Link K, Khatwani N, Reynders J, Moore MJ, et al. mRNA structure regulates protein expression through changes in functional half-life. Proc Natl Acad Sci USA. 2019;116(48):24075–83. doi:10.1073/pnas.1908052116.
   PubMed Web of Science ®Google Scholar
• Wayment-Steele HK, Kim DS, Choe CA, Nicol JJ, Wellington-Oguri R, Watkins AM, Parra Sperberg RA, Huang PS, Participants E, Das R. Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic Acids Res. 2021;49(18):10604–17. doi:10.1093/nar/gkab764.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, Liu B, Ma X, Zhao F, Jiang H, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621(7978):396–403. doi:10.1038/s41586-023-06127-z.
   PubMed Web of Science ®Google Scholar
• Trepotec Z, Geiger J, Plank C, Aneja MK, Rudolph C. Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life. RNA. 2019;25(4):507–18. doi:10.1261/rna.069286.118.
   PubMed Web of Science ®Google Scholar
• Xia X. Detailed dissection and critical evaluation of the Pfizer/BioNTech and moderna mRNA vaccines. Vaccines. 2021;9(7):734. doi:10.3390/vaccines9070734.
   PubMed Web of Science ®Google Scholar
• Li CY, Liang Z, Hu Y, Zhang H, Setiasabda KD, Li J, Ma S, Xia X, Kuang Y. Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo. Mol Ther Nucleic Acids. 2022;30:300–10. doi:10.1016/j.omtn.2022.10.003.
   PubMedGoogle Scholar
• Mostafa D, Takahashi A, Yanagiya A, Yamaguchi T, Abe T, Kureha T, Kuba K, Kanegae Y, Furuta Y, Yamamoto T, et al. Essential functions of the CNOT7/8 catalytic subunits of the CCR4-NOT complex in mRNA regulation and cell viability. RNA Biol. 2020;17(3):403–16. doi:10.1080/15476286.2019.1709747.
   PubMed Web of Science ®Google Scholar
• McKay PF, Hu K, Blakney AK, Samnuan K, Brown JC, Penn R, Zhou J, Bouton CR, Rogers P, Polra K, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun. 2020;11(1):3523. doi:10.1038/s41467-020-17409-9.
   PubMed Web of Science ®Google Scholar
• Pollock KM, Cheeseman HM, Szubert AJ, Libri V, Boffito M, Owen D, Bern H, O’Hara J, McFarlane LR, Lemm NM, et al. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine. 2022;44:101262. doi:10.1016/j.eclinm.2021.101262.
   PubMedGoogle Scholar
• Ramos da Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva M, Porchia B, Moreno ACR, Aps L, Venceslau-Carvalho AA, et al. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med. 2023;15(686):eabn3464. doi:10.1126/scitranslmed.abn3464.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022;348:84–94. doi:10.1016/j.jconrel.2022.05.043.
   PubMed Web of Science ®Google Scholar
• Obi P, Chen YG. The design and synthesis of circular RNAs. Methods. 2021;196:85–103. doi:10.1016/j.ymeth.2021.02.020.
   PubMed Web of Science ®Google Scholar
• Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H, Zhang X, Tian F, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728–44.e1716. doi:10.1016/j.cell.2022.03.044.
   PubMed Web of Science ®Google Scholar
• Li H, Peng K, Yang K, Ma W, Qi S, Yu X, He J, Lin X, Yu G. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics. 2022;12(14):6422–36. doi:10.7150/thno.77350.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhu J, Sun J, Chen Y, Du Y, Tan Y, Wu L, Zhai M, Wei L, Li N, et al. Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy. Mol Ther Nucleic Acids. 2022;30:184–97. doi:10.1016/j.omtn.2022.09.010.
   PubMedGoogle Scholar
• Amaya L, Grigoryan L, Li Z, Lee A, Wender PA, Pulendran B, Chang HY. Circular RNA vaccine induces potent T cell responses. Proc Natl Acad Sci USA. 2023;120(20):e2302191120. doi:10.1073/pnas.2302191120.
   PubMed Web of Science ®Google Scholar
• Huang D, Zhu X, Ye S, Zhang J, Liao J, Zhang N, Zeng X, Wang J, Yang B, Zhang Y, et al. Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature. 2023. doi:10.1038/s41586-023-06834-7.
   Google Scholar
• Tockary TA, Abbasi S, Matsui-Masai M, Hayashi A, Yoshinaga N, Boonstra E, Wang Z, Fukushima S, Kataoka K, Uchida S. Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment. Proc Natl Acad Sci USA. 2023;120(29):e2214320120. doi:10.1073/pnas.2214320120.
   PubMedGoogle Scholar
• Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401. doi:10.1038/nature18300.
   PubMed Web of Science ®Google Scholar
• Tan Y, Lu S, Wang B, Duan X, Zhang Y, Peng X, Li H, Lin A, Zhan Z, Liu X. Single-cell transcriptome atlas reveals protective characteristics of COVID-19 mRNA vaccine. J Med Virol. 2023;95(1):e28161. doi:10.1002/jmv.28161.
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017;34:123–32. doi:10.1016/j.smim.2017.08.014.
   PubMed Web of Science ®Google Scholar
• Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, Wang P, Su X, Qin Y, Wang Y, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Sig Transduct Target Ther. 2021;6(1):26. doi:10.1038/s41392-020-00448-5.
   PubMed Web of Science ®Google Scholar
• Wang Z, Ma W, Fu X, Qi Y, Zhao Y, Zhang S. Development and applications of mRNA treatment based on lipid nanoparticles. Biotechnol Adv. 2023;65:108130. doi:10.1016/j.biotechadv.2023.108130.
   PubMed Web of Science ®Google Scholar
• Kiaie SH, Majidi Zolbanin N, Ahmadi A, Bagherifar R, Valizadeh H, Kashanchi F, Jafari R. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnol. 2022;20(1):276. doi:10.1186/s12951-022-01478-7.
   PubMed Web of Science ®Google Scholar
• Kauffman KJ, Webber MJ, Anderson DG. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release. 2016;240:227–34. doi:10.1016/j.jconrel.2015.12.032.
   PubMed Web of Science ®Google Scholar
• Patel S, Ashwanikumar N, Robinson E, Xia Y, Mihai C, Griffith JP 3rd, Hou S, Esposito AA, Ketova T, Welsher K, et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat Commun. 2020;11(1):983. doi:10.1038/s41467-020-14527-2.
   PubMed Web of Science ®Google Scholar
• Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172–6. doi:10.1038/nbt.1602.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. doi:10.1056/NEJMoa1716153.
   PubMed Web of Science ®Google Scholar
• Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater. 2023a;35(51):e2303261. doi:10.1002/adma.202303261.
   PubMedGoogle Scholar
• Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater. 2023b:e2303261. doi:10.1002/adma.202303261.
   PubMedGoogle Scholar
• Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol. 2023;20(11):739–54. doi:10.1038/s41571-023-00811-9.
   PubMed Web of Science ®Google Scholar
• Nakamura-Nishimura Y, Shinkuma S, Miyagawa F, Haredy A, Gomi Y, Yamanishi K, Asada H. Immunogenicity of varicella-zoster virus vaccine by different routes of administration: Comparable vaccination efficacy of one-fifth dose intradermal vaccination to conventional subcutaneous vaccination. J Dermatol Sci. 2022;106(2):86–92. doi:10.1016/j.jdermsci.2022.04.001.
   PubMed Web of Science ®Google Scholar
• Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–80. doi:10.1038/nrd4278.
   PubMed Web of Science ®Google Scholar
• Zhang H, You X, Wang X, Cui L, Wang Z, Xu F, Li M, Yang Z, Liu J, Huang P, et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc Natl Acad Sci USA. 2021;118(6). doi:10.1073/pnas.2005191118.
   Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79. doi:10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, Schlenk F, Fischer D, Kiouptsi K, Reinhardt C, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772–81. doi:10.1038/nnano.2013.181.
   PubMed Web of Science ®Google Scholar
• Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C, Evans J, Henske EP, Xu Q. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2022;119(8). doi:10.1073/pnas.2116271119.
   Web of Science ®Google Scholar
• Yang Z, Liu Y, Zhao K, Jing W, Gao L, Dong X, Wang Y, Han M, Shi C, Tang C, et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J Control Release. 2023;360:718–33. doi:10.1016/j.jconrel.2023.07.021.
   PubMed Web of Science ®Google Scholar
• Zhao X, Chen J, Qiu M, Li Y, Glass Z, Xu Q. Imidazole-based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes. Angew Chem Int Ed Engl. 2020;59(45):20083–89. doi:10.1002/anie.202008082.
   PubMed Web of Science ®Google Scholar
• Chen J, Ye Z, Huang C, Qiu M, Song D, Li Y, Xu Q. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response. Proc Natl Acad Sci USA. 2022;119(34):e2207841119. doi:10.1073/pnas.2207841119.
   PubMed Web of Science ®Google Scholar
• Paunovska K, Sago CD, Monaco CM, Hudson WH, Castro MG, Rudoltz TG, Kalathoor S, Vanover DA, Santangelo PJ, Ahmed R, et al. A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation. Nano Lett. 2018;18(3):2148–57. doi:10.1021/acs.nanolett.8b00432.
   PubMed Web of Science ®Google Scholar
• Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H. Nanoparticle uptake: the phagocyte problem. Nano Today. 2015;10(4):487–510. doi:10.1016/j.nantod.2015.06.006.
   PubMed Web of Science ®Google Scholar
• Kowalski PS, Capasso Palmiero U, Huang Y, Rudra A, Langer R, Anderson DG. Ionizable amino-polyesters synthesized via ring opening polymerization of tertiary amino-alcohols for tissue selective mRNA delivery. Adv Mater. 2018;30(34):e1801151. doi:10.1002/adma.201801151.
   Web of Science ®Google Scholar
• Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313–20. doi:10.1038/s41565-020-0669-6.
   PubMed Web of Science ®Google Scholar
• Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci USA. 2021;118(52). doi:10.1073/pnas.2109256118.
   PubMedGoogle Scholar
• Igyártó BZ, Jacobsen S, Ndeupen S. Future considerations for the mRNA-lipid nanoparticle vaccine platform. Curr Opin Virol. 2021;48:65–72. doi:10.1016/j.coviro.2021.03.008.
   PubMed Web of Science ®Google Scholar
• Martin D, Gutkind JS. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene. 2008;Suppl 27(S2):S31–42. doi:10.1038/onc.2009.351.
   Google Scholar
• Pietropaolo V, Prezioso C, Moens U. Role of virus-induced host cell epigenetic changes in cancer. Int J Mol Sci. 2021;22(15):8346. doi:10.3390/ijms22158346.
   PubMed Web of Science ®Google Scholar
• Saha A, Kaul R, Murakami M, Robertson ES. Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention. Cancer Biol Ther. 2010;10(10):961–78. doi:10.4161/cbt.10.10.13923.
   PubMed Web of Science ®Google Scholar
• Cheng L, Wang Y, Du J. Human papillomavirus vaccines: an updated review. Vaccines. 2020;8(3):391. doi:10.3390/vaccines8030391.
   PubMed Web of Science ®Google Scholar
• Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccines. J Infect Dis. 2021;224(12 Suppl 2):S343–51. doi:10.1093/infdis/jiaa668.
   PubMedGoogle Scholar
• Zhai L, Tumban E. Gardasil-9: a global survey of projected efficacy. Antiviral Res. 2016;130:101–09. doi:10.1016/j.antiviral.2016.03.016.
   PubMed Web of Science ®Google Scholar
• Lee S, Yoon H, Hong SH, Kwon SP, Hong JJ, Kwak HW, Park HJ, Yoo S, Bae SH, Park HJ, et al. mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization. J Med Virol. 2023;95(12):e29309. doi:10.1002/jmv.29309.
   PubMedGoogle Scholar
• Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503(7475):224–8. doi:10.1038/nature12744.
   PubMed Web of Science ®Google Scholar
• Zhang P, Narayanan E, Liu Q, Tsybovsky Y, Boswell K, Ding S, Hu Z, Follmann D, Lin Y, Miao H, et al. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat Med. 2021;27(12):2234–45. doi:10.1038/s41591-021-01574-5.
   PubMed Web of Science ®Google Scholar
• Leggat DJ, Cohen KW, Willis JR, Fulp WJ, deCamp AC, Kalyuzhniy O, Cottrell CA, Menis S, Finak G, Ballweber-Fleming L, et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 2022;378(6623):eadd6502. doi:10.1126/science.add6502.
   PubMed Web of Science ®Google Scholar
• Chen B, Chen Y, Li J, Wang C, Song W, Wen Y, Lin J, Wu Y, Ying T, Zheng C. A single dose of anti-HBsAg antibody-encoding mRNA-LNPs suppressed HBsAg expression: a potential cure of chronic hepatitis B virus infection. mBio. 2022;13(4):e0161222. doi:10.1128/mbio.01612-22.
   PubMed Web of Science ®Google Scholar
• Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer. 2016;16(12):789–802. doi:10.1038/nrc.2016.92.
   PubMed Web of Science ®Google Scholar
• Guo M, Duan X, Peng X, Jin Z, Huang H, Xiao W, Zheng Q, Deng Y, Fan N, Chen K, et al. A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma. Nano Res. 2023;16(4):5357–67. doi:10.1007/s12274-022-5254-x.
   PubMed Web of Science ®Google Scholar
• van Zyl DG, Mautner J, Delecluse HJ. Progress in EBV Vaccines. Front Oncol. 2019;9:104. doi:10.3389/fonc.2019.00104.
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–47. doi:10.1056/NEJMoa0810097.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200. doi:10.1136/bmj.m2200.
   PubMedGoogle Scholar
• Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188(12):2205–13. doi:10.1084/jem.188.12.2205.
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Tagliamonte M. Selecting target antigens for cancer vaccine development. Vaccines. 2020;8(4):615. doi:10.3390/vaccines8040615.
   Web of Science ®Google Scholar
• Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121(3):439–62. doi:10.1084/jem.121.3.439.
   PubMed Web of Science ®Google Scholar
• Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003;22(42):6570–78. doi:10.1038/sj.onc.1206779.
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 1997;118(2):153–60. doi:10.1016/s0304-3835(97)00326-1.
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643–47. doi:10.1126/science.1840703.
   PubMed Web of Science ®Google Scholar
• Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem. 1990;265(25):15286–93. doi:10.1016/S0021-9258(18)77254-2.
   PubMed Web of Science ®Google Scholar
• Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. J Urol. 2017;197(2s):S148–52. doi:10.1016/j.juro.2016.10.100.
   PubMedGoogle Scholar
• Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94(5):1914–18. doi:10.1073/pnas.94.5.1914.
   PubMed Web of Science ®Google Scholar
• Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, Soma T, Tatekawa T, Kawakami M, Asada M, et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90(2):194–204. doi:10.1111/j.1349-7006.1999.tb00733.x.
   PubMedGoogle Scholar
• Crandall BF, Lau HL. Alpha-fetoprotein: a review. Crit Rev Clin Lab Sci. 1981;15(2):127–85. doi:10.3109/10408368109105870.
   PubMed Web of Science ®Google Scholar
• Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306(1):16–25. doi:10.1016/s0006-291x(03)00908-2.
   PubMed Web of Science ®Google Scholar
• Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 1997;57:2865–9.
   PubMed Web of Science ®Google Scholar
• Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4(1):7. doi:10.1038/s41541-019-0103-y.
   PubMed Web of Science ®Google Scholar
• He Q, Gao H, Tan D, Zhang H, Wang JZ. mRNA cancer vaccines: advances, trends and challenges. Acta Pharm Sin B. 2022;12(7):2969–89. doi:10.1016/j.apsb.2022.03.011.
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–81. doi:10.1038/nature13988.
   PubMed Web of Science ®Google Scholar
• Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400–404. doi:10.1038/nature10755.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747–52. doi:10.1038/nm.3161.
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107–12. doi:10.1038/s41586-020-2537-9.
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–45. doi:10.1126/science.1251102.
   PubMed Web of Science ®Google Scholar
• Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387–90. doi:10.1126/science.aad1253.
   PubMed Web of Science ®Google Scholar
• Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon PO, Kandalaft LE, Coukos G, Gfeller D, Hertz T. Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Comput Biol. 2017;13(8):e1005725. doi:10.1371/journal.pcbi.1005725.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim HS, Kim E, Lee MG, Shin EC, Paik S, Kim S. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information. Ann Oncol. 2018;29(4):1030–6. doi:10.1093/annonc/mdy022.
   PubMed Web of Science ®Google Scholar
• Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008;68(3):889–92. doi:10.1158/0008-5472.Can-07-3095.
   PubMed Web of Science ®Google Scholar
• Xu H, Zheng X, Zhang S, Yi X, Zhang T, Wei Q, Li H, Ai J. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma. Mol Cancer. 2021;20(1):159. doi:10.1186/s12943-021-01465-w.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–6. doi:10.1038/nature23003.
   PubMed Web of Science ®Google Scholar
• mRNA Vaccine Slows Melanoma Recurrence. Cancer Discov. 2023;13(6):1278. doi:10.1158/2159-8290.Cd-nb2023-0028.
   Web of Science ®Google Scholar
• Hsu SK, Jadhao M, Liao WT, Chang WT, Hung CT, Chiu CC. Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: tumour microenvironment components. Front Mol Biosci. 2022;9:1020888. doi:10.3389/fmolb.2022.1020888.
   PubMed Web of Science ®Google Scholar
• Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–50. doi:10.1038/s41586-023-06063-y.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Chen J, Zhou H, Zeng X, Ruan Z, Pu Z, Jiang X, Matsui A, Zhu L, Amoozgar Z, et al. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat Commun. 2022;13(1):758. doi:10.1038/s41467-022-28279-8.
   PubMed Web of Science ®Google Scholar
• Van Lint S, Renmans D, Broos K, Goethals L, Maenhout S, Benteyn D, Goyvaerts C, Du Four S, Van der Jeught K, Bialkowski L, et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res. 2016;4(2):146–56. doi:10.1158/2326-6066.Cir-15-0163.
   PubMed Web of Science ®Google Scholar